{"id":"iv-pantoprazole","safety":{"commonSideEffects":[{"rate":"12-18%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"4-8%","effect":"Nausea"},{"rate":"3-6%","effect":"Abdominal pain"},{"rate":"2-5%","effect":"Injection site reactions"},{"rate":"1-2%","effect":"Hypomagnesemia"}]},"_chembl":{"chemblId":"CHEMBL1502","moleculeType":"Small molecule","molecularWeight":"383.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pantoprazole is a proton pump inhibitor (PPI) that irreversibly binds to and inactivates the H+/K+-ATPase enzyme on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, reducing intragastric pH and providing rapid acid suppression. The IV formulation allows for direct systemic delivery in patients unable to take oral medication.","oneSentence":"IV pantoprazole inhibits gastric acid secretion by blocking the proton pump (H+/K+-ATPase) in parietal cells of the stomach.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:34.553Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Stress ulcer prophylaxis in critically ill patients"},{"name":"Zollinger-Ellison syndrome"}]},"trialDetails":[{"nctId":"NCT06154226","phase":"PHASE2","title":"Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2024-01-10","conditions":"Acute Kidney Injury","enrollment":100},{"nctId":"NCT04394663","phase":"NA","title":"High Dose Oral Omeprazole in High Risk UGIB","status":"RECRUITING","sponsor":"King Chulalongkorn Memorial Hospital","startDate":"2020-10-01","conditions":"GI Bleeding","enrollment":128},{"nctId":"NCT07032883","phase":"NA","title":"Benson Relaxation Technique Effectiveness on Pain and Quality of Life Post Reconstructive Mammoplasty","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2025-06-25","conditions":"Breast Cancer","enrollment":68},{"nctId":"NCT02401035","phase":"PHASE4","title":"PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects","status":"TERMINATED","sponsor":"Pfizer","startDate":"2017-05-09","conditions":"Gastroesophageal Reflux Disease","enrollment":19},{"nctId":"NCT05005910","phase":"EARLY_PHASE1","title":"Efficacy of Vonoprazan Versus Intravenous Proton Pump Inhibitors for Prevention of Rebleeding in High Risk Peptic Ulcers Bleeding After Successful Endoscopic Hemostasis","status":"COMPLETED","sponsor":"Uayporn Kaosombatwattana","startDate":"2021-09-01","conditions":"Peptic Ulcer With Haemorrhage","enrollment":194},{"nctId":"NCT06062719","phase":"PHASE2, PHASE3","title":"Role of Octreotide in Non Variceal Bleeding","status":"UNKNOWN","sponsor":"National Hepatology & Tropical Medicine Research Institute","startDate":"2023-08-23","conditions":"Non-variceal Gastrointestinal Bleeding","enrollment":56},{"nctId":"NCT02929563","phase":"PHASE3","title":"Pediatric Intensive Care Ulcer Prophylaxis Pilot Trial","status":"COMPLETED","sponsor":"McMaster University","startDate":"2017-01-09","conditions":"Gastrointestinal Hemorrhage","enrollment":116},{"nctId":"NCT01848457","phase":"PHASE2","title":"Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2013-04","conditions":"Osteosarcoma, Nephrotoxicity, Ototoxicity","enrollment":13},{"nctId":"NCT02987920","phase":"PHASE4","title":"Dextromethorphan Use in Multimodal Analgesia Regimens for Total Knee Arthroplasty","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2017-01","conditions":"Pain, Postoperative","enrollment":23},{"nctId":"NCT01477320","phase":"NA","title":"Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.","status":"COMPLETED","sponsor":"Mohamed Saad","startDate":"2013-09","conditions":"Gastrointestinal Hemorrhage, Clostridium Difficile Colitis","enrollment":124},{"nctId":"NCT02788123","phase":"PHASE4","title":"A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Subjects With Nonsteroidal Anti-Inflammatory Drugs (NSAID)-Induced Gastropathy","status":"TERMINATED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2017-03-03","conditions":"NSAID-induced Gastropathy","enrollment":9},{"nctId":"NCT02502877","phase":"NA","title":"Core Temperature Variations During Midazolam vs Propofol Sedation for Neuraxial Anesthesia","status":"COMPLETED","sponsor":"Hospital da Luz, Portugal","startDate":"2015-07","conditions":"Body Temperature Changes, Anesthesia","enrollment":27},{"nctId":"NCT00744419","phase":"PHASE1","title":"Intravenous (IV) Pantoprazole for Gastroesophageal Reflux Disease (GERD) in Neonates and Infants","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2009-05","conditions":"Gastroesophageal Reflux","enrollment":24},{"nctId":"NCT01163903","phase":"PHASE1","title":"Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2010-07","conditions":"Advanced Solid Tumours","enrollment":24},{"nctId":"NCT02214433","phase":"PHASE1","title":"A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2014-08","conditions":"Bacterial Infections","enrollment":70},{"nctId":"NCT00699361","phase":"PHASE3","title":"Influence of Pantoprazole on Human Myocardial Contractility at Patients With Congestive Heart Failure","status":"WITHDRAWN","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2008-08","conditions":"Congestive Heart Failure","enrollment":""},{"nctId":"NCT00839488","phase":"PHASE4","title":"Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis","status":"TERMINATED","sponsor":"Far Eastern Memorial Hospital","startDate":"2008-04","conditions":"Stomach Ulcer","enrollment":6},{"nctId":"NCT00133770","phase":"PHASE4","title":"Intravenous (IV) Pantoprazole in Erosive Esophagitis","status":"COMPLETED","sponsor":"Emory University","startDate":"2004-07","conditions":"Esophagitis","enrollment":20},{"nctId":"NCT01182597","phase":"PHASE3","title":"Oral Versus IV Proton Pump Inhibitor in High-risk Bleeding Peptic Ulcers After Endoscopic Hemostasis","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2010-08","conditions":"Peptic Ulcers","enrollment":190},{"nctId":"NCT00206050","phase":"PHASE4","title":"Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Healthy","enrollment":40},{"nctId":"NCT01179724","phase":"NA","title":"Comparison of Proton Pump Inhibitor and H2 Receptor Blocker on Prevention of Bleeding From Iatrogenic Ulcer After Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2009-07","conditions":"Delayed Bleeding","enrollment":206},{"nctId":"NCT00709046","phase":"NA","title":"High Dose Versus Standard Dose Proton Pump Inhibitor (PPI) in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Treatment","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2008-01","conditions":"Endoscopy, Peptic Ulcer, Bleeding","enrollment":150},{"nctId":"NCT00731601","phase":"PHASE4","title":"Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding","status":"COMPLETED","sponsor":"Lotung Poh-Ai Hospital","startDate":"2008-05","conditions":"Peptic Ulcer Hemorrhage","enrollment":120},{"nctId":"NCT00600041","phase":"PHASE1","title":"Placebo-Controlled Crossover Study for the Investigation of the Effect of Pantoprazole on Cardiac Contractility","status":"COMPLETED","sponsor":"Herzzentrum Goettingen","startDate":"2005-05","conditions":"Healthy","enrollment":20}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BLOOD PRESSURE INCREASED"},{"count":1,"reaction":"CHEST X-RAY ABNORMAL"},{"count":1,"reaction":"CHILLS"},{"count":1,"reaction":"CONSTIPATION"},{"count":1,"reaction":"CROHN^S DISEASE"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"FAECAL CALPROTECTIN INCREASED"},{"count":1,"reaction":"HEART RATE INCREASED"},{"count":1,"reaction":"INFUSION RELATED REACTION"},{"count":1,"reaction":"LEUKOCYTOSIS"}],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"IV pantoprazole","genericName":"IV pantoprazole","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IV pantoprazole inhibits gastric acid secretion by blocking the proton pump (H+/K+-ATPase) in parietal cells of the stomach. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Stress ulcer prophylaxis in critically ill patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}